Intensifying criticism from academia, the media, and regulators has been directed at perceived bias in the large proportion of CME content that often favors a newly marketed product or off-label use of a product manufactured by the sponsor. The Senate report is primarily concerned about such influence on drug expenditures for Medicare and Medicaid.Click here to read the article.
Friday, April 04, 2008
Psychiatric News article on CME and pharma influence
An excerpt:
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment